BioCentury
ARTICLE | Financial News

Philogen bypasses VCs, taps Italian syndicate for €62M to fuel late stage cancer programs

May 13, 2019 9:32 PM UTC

With €62 million ($69.6 million) in series A cash to carry its two late-stage candidates through clinical development, Philogen will soon have to decide whether to rely on additional deals to find commercialization partners, or establish its own sales force.

The funds will push the company's two lead candidates through to registration, Philogen S.p.A. (Siena, Italy) co-founder Dario Neri told BioCentury. Both use antibody fusion constructs to deliver cytokine payloads; Daromun (L19IL2/L19TNF) is in a Phase III trial for fully resectable stage III B/C melanoma, while Fibromun (L19-TNF) is in a Phase III study to treat metastatic soft tissue sarcoma. ...